Objective To study the effect of hypoglycemic agents on endothelial progenitor cells (EPC) marked with CD34 and VEGFR-2 in elderly patients with coronary heart disease(CHD) accompanying diabetes mellitus (DM). Methods Eighty-five CHD patients accompanying DM were divided into CHD group(?= 41)and CHD accompanying DM group(??=44). Their CD34 and VEGFR-2 positive EPC(CD34+/VEGFR-2+ EPC) were detected by flow cytometry. Patients in CHD accompanying DM group were treated with hypoglycemic agents and followed up 4 weeks after their blood glucose became stable, during which the.CD34 + and VEGFR-2+ EPC were observed. Results The percentage of CD34+ and VEGFR-2+ EPC was significantly lower in CHD accompanying DM group than in CHD group(P<0. 05) and significantly higher in CHD accompanying DM group after treatment than before treatment with hypoglycaemic agents(P<0. 05). The percentage of CD34+ and VEGFR-2+ EPC was negatively related with the HbAlc in CHD accompanying DM group(r= ?. 771, P<0. 05). Conclusion Treatment of elderly CHD patients accompanying DM with hypoglycemic agents can alleviate the effect of high blood glucose level on CD34+ and VEGFR-2+ EPC,and is thus beneficial for delaying the progress of atherosclerosis.%目的 探讨降糖药物对老年冠心病合并糖尿病患者外周血CD34与血管内皮生长因子受体2(VEGFR-2)共同标记的血管内皮祖细胞(EPC)水平的影响.方法 选择确诊的冠心病患者85例,根据口服葡萄糖耐量试验结果分为冠心病组41例,冠心病合并糖尿病组(合并组)44例,采用流式细胞仪检测2组外周血CD34及VEGFR-2双阳性的EPC(CD34+/VEGFR-2+ EPC)水平；合并组患者降糖治疗,血糖稳定4周后门诊随访,观察外周血CD34+/VEGFR-2+ EPC水平的变化.结果 合并组外周血CD34+/VEGFR-2+ EPC水平较冠心病组明显降低(P＜0.05)；合并组治疗后外周血CD34 +/VEGFR-2+ EPC水平较治疗前明显上升(P＜0.05)；EPC百分比与糖化血红蛋白水平呈负相关(r=-0.771,P＜0.05).结论 降糖治疗可减轻高血糖水平对CD34 +/VEGFR-2+的影响,使EPC耗损减少,有利于减缓冠状动脉粥样硬化进程.
展开▼
